Zacks Research Issues Optimistic Forecast for GSK Earnings

GSK plc (NYSE:GSK) – Equities research analysts at Zacks Research increased their FY2025 earnings estimates for GSK in a research report issued to clients and investors on Wednesday, February 26th. Zacks Research analyst E. Bagri now anticipates that the pharmaceutical company will earn $4.14 per share for the year, up from their previous forecast of $4.12. The consensus estimate for GSK’s current full-year earnings is $4.14 per share. Zacks Research also issued estimates for GSK’s Q4 2025 earnings at $0.76 EPS.

GSK has been the subject of several other research reports. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Morgan Stanley initiated coverage on shares of GSK in a research report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and dropped their price target for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Seven investment analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Stock Performance

GSK stock opened at $37.97 on Monday. The company has a market capitalization of $78.70 billion, a P/E ratio of 23.88, a PEG ratio of 1.12 and a beta of 0.64. The company has a 50-day simple moving average of $35.07 and a 200 day simple moving average of $37.20. GSK has a fifty-two week low of $31.72 and a fifty-two week high of $45.92. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%.

Institutional Trading of GSK

Several institutional investors and hedge funds have recently bought and sold shares of the stock. BridgePort Financial Solutions LLC acquired a new stake in GSK during the 4th quarter worth about $310,000. Total Wealth Planning & Management Inc. acquired a new stake in GSK during the 4th quarter worth about $390,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in GSK during the 4th quarter worth about $13,730,000. Brucke Financial Inc. acquired a new stake in GSK during the 4th quarter worth about $465,000. Finally, Yoffe Investment Management LLC acquired a new stake in GSK during the 4th quarter worth about $462,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be issued a dividend of $0.3932 per share. This represents a $1.57 annualized dividend and a yield of 4.14%. The ex-dividend date is Friday, February 21st. This is an increase from GSK’s previous quarterly dividend of $0.39. GSK’s payout ratio is presently 98.74%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.